Pfizer pediatric COVID vaccine EUA

FDA May Limit Pfizer’s Pediatric COVID Vaccine Authorization, Raising Concerns for Fall Immunizations

The availability of COVID-19 vaccines for young children in the U.S. could shrink this fall as the Food and Drug Administration (FDA) considers ending the emergency use authorization (EUA) for Pfizer-BioNTech’s vaccine in kids ages 6 months to 4 years. Pfizer says it is in discussions with the FDA and has asked to keep the

Alzheimer disease hereditary

New Dosing for Lilly Alzheimer’s Drug Shows Safer Profile

The FDA has approved a safer dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E—brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will

What is COPD, Nucala for COPD treatment

FDA Approves Nucala for COPD Patients with High Eosinophil Levels

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on treatment for adults with chronic obstructive pulmonary disease (COPD) who continue to have flare-ups despite using triple inhaled therapy. Nucala is the first biologic drug specifically approved for COPD patients with an “eosinophilic phenotype”—a group defined by having high levels of